Rifaximin: Difference between revisions
m (Protected "Rifaximin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +)) |
||
| Line 23: | Line 23: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''Rifaximin''' is a semisynthetic, [[rifamycin]]-based non-systemic [[antibiotic]], meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It is licensed for use to treat diarrhea caused by ''[[Escherichia coli|E. coli]]''. It is not effective against ''[[Campylobacter jejuni]]'', and there is no evidence of efficacy against ''[[Shigella]]'' or ''[[Salmonella]]'' species. | '''Rifaximin''' is a semisynthetic, [[rifamycin]]-based non-systemic [[antibiotic]], meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It is licensed for use to treat diarrhea caused by ''[[Escherichia coli|E. coli]]''. It is not effective against ''[[Campylobacter jejuni]]'', and there is no evidence of efficacy against ''[[Shigella]]'' or ''[[Salmonella]]'' species. | ||
| Line 49: | Line 49: | ||
{{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}} | {{Antidiarrheals, intestinal anti-inflammatory/anti-infective agents}} | ||
{{Antibiotics and chemotherapeutics for dermatological use}} | {{Antibiotics and chemotherapeutics for dermatological use}} | ||
[[hu:Rifaximin]] | [[hu:Rifaximin]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 15:44, 20 August 2012
| File:Rifaximin.svg | |
| File:Rifaximin Xifaxan.gif | |
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | < 0.4% |
| Metabolism | Hepatic |
| Elimination half-life | 6 hours |
| Excretion | Fecal (97%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C43H51N3O11 |
| Molar mass | 785.879 g/mol |
|
WikiDoc Resources for Rifaximin |
|
Articles |
|---|
|
Most recent articles on Rifaximin |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Rifaximin at Clinical Trials.gov Clinical Trials on Rifaximin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Rifaximin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Rifaximin Discussion groups on Rifaximin Directions to Hospitals Treating Rifaximin Risk calculators and risk factors for Rifaximin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Rifaximin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It is licensed for use to treat diarrhea caused by E. coli. It is not effective against Campylobacter jejuni, and there is no evidence of efficacy against Shigella or Salmonella species.
It may be efficacious in relieving chronic functional symptoms of bloating and flatulence that are common in irritable bowel syndrome.[1]
In 2005, it received orphan drug status for the treatment of hepatic encephalopathy.[2]
It is currently sold in the U.S. under the brand name Xifaxan by Salix Pharmaceuticals.
It's also sold in Europe under the name Spiraxin and Zaxine, both of which seem to be cheaper solutions. There isn't a generic version of the drug.
References
- ↑ Sharara A, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, ElHajj I. (2006). "A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence". Am J Gastroenterol. 101 (2): 326.
- ↑ Wolf, David C. (2007-01-09). "Hepatic Encephalopathy". eMedicine. WebMD. Retrieved 2007-02-15. Check date values in:
|date=(help)
- Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. National Committee for Clinical Laboratory Standards, Sixth Edition, Wayne PA. — January 2003
- Micromedex information on rifaximin
- FDA label approved for Xifaxan (PDF warning)
External links
- Xifaxan® (manufacturer's website)
Template:Antidiarrheals, intestinal anti-inflammatory/anti-infective agents
- Pages with script errors
- CS1 maint: Multiple names: authors list
- CS1 errors: dates
- Pages with broken file links
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Orphan drugs
- Rifamycin antibiotics